BioLoomics develops a human-cell directed evolution platform to discover and engineer antibodies that drive target degradation and other spatial activities. The company combines synthetic biology, computer vision–guided cell picking, imaging, robotics, and machine learning to search antibody design space at high throughput. BioLoomics says its platform enables testing of antibody designs ~10,000x more than legacy methods and is adaptable across a wide variety of target classes. The team intends to use its technology to create safer, more effective cancer therapeutics by manipulating intracellular antibody trafficking. With the new capital, BioLoomics will advance proprietary platform technology and antibody degrader programs, develop pre-clinical assets, and pursue strategic partnerships with large pharma. The company is headquartered in Colorado and is actively recruiting for CSO and CTO roles; Dr. Nick Saccomano recently joined as an Independent Board Director.

Total raised

$9M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2023